Aptamers News and Research

RSS

Aptamer Group and AstraZeneca to develop new drug delivery vehicles

Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney.

From AstraZeneca 10 Jan 2019

New bioinspired material interacts with surrounding tissues to promote wound healing

Imperial researchers have developed new bioinspired material that interacts with surrounding tissues to promote healing.

7 Jan 2019

New technique detects, measures, analyzes unevenly charged biomolecules

In clinical diagnostics, it is critical to monitor biomolecules in a simple, rapid and sensitive way. Clinicians most often monitor antibodies because these small proteins attach to antigens, or foreign substances, we face every day.

17 Aug 2018

Researchers show how specialized nucleic acid-based nanostructures could help target cancer cells

More than 100 years ago, German Nobel laureate Paul Ehrlich popularized the "magic bullet" concept -- a method that clinicians might one day use to target invading microbes without harming other parts of the body. Although chemotherapies have been highly useful as targeted treatments for cancer, unwanted side effects still plague patients.

14 Aug 2018

A Multi-Modal Approach for the Early Detection of Breast Cancer

Professor Samir Iqbal describes his research in the field of breast cancer detection and how machine learning can improve early diagnosis rates.

16 Jul 2018

Researcher develops nanoparticle-based tags to detect viruses and cancer with high sensitivity

How can we detect cancer and viruses with high sensitivity? Physical chemist Laura Fabris - an associate professor in the Materials Science and Engineering Department at Rutgers, the State University of New Jersey, and principal investigator of the Fabris NanoBio Group - is addressing this very question.

22 May 2018

UC scientists identify protein that acts as mediator of HER2-driven breast cancer

Researchers at the University of Cincinnati College of Medicine have identified for the first time that the estrogen receptor-binding protein MED1 is a critical mediator of HER2-driven breast cancer, identifying it as a potential therapeutic target.

9 Jan 2018

New system makes it easier to detect rare molecules linked to early disease

By attaching specialized molecules to the backbone of DNA, researchers have made it easier to detect rare molecules associated with early disease.

20 Dec 2017

HKBU experts develop new generation of smart anti-cancer drug molecules

The toxic nature of chemotherapy poses a great challenge to clinical treatment of cancer. A team of scholars from the School of Chinese Medicine of Hong Kong Baptist University devoted their efforts to the development of a new generation of smart anti-cancer drug molecules.

15 Dec 2017

Researchers use RNA nanotechnology to program exosomes for delivering effective cancer therapies

A new study shows that attaching antibody-like RNA nanoparticles to microvesicles can deliver effective RNA therapeutics such as small interfering RNA specifically to cancer cells.

13 Dec 2017

Caris Life Sciences reveals identification of new mechanism of action to treat NHL

Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced a data presentation, at the 59th American Society of Hematology Annual Meeting & Exposition in Atlanta, demonstrating the identification of a new mechanism of action to treat non-Hodgkin lymphoma (NHL).

13 Dec 2017

Study focuses on improving pharmacokinetic properties of therapeutic aptamers

Designing new therapeutic DNA aptamers with diverse side chains can improve their ability to interact with targets, and a new study describes characteristics of these side chains that may determine how long the aptamers remain in the bloodstream.

30 Nov 2017

Bioengineers develop brain sensor technique to understand cocaine addiction in adolescent mind

Several studies have provided strong evidence that adolescents--people in their teens to early twenties--have a higher vulnerability than adults to addictive substances like cocaine.

1 Nov 2017

Researchers isolate new molecule suitable for control of contact allergies

Researchers from the University of Bonn have isolated a molecule that is suitable for the control of contact allergies. The study illuminates a central immune mechanism, which may also play a role in other inflammatory diseases such as arthritis or arteriosclerosis.

30 Oct 2017

IBN researchers create DNA technology with two new genetic alphabets

Just like how alphabets are strung together to form words, our DNA is also strung together by alphabets to encode proteins. Our DNA contains only 4 natural genetic alphabets - A, C, G and T, which hold the blueprint for the production of proteins that make our bodies work.

26 Oct 2017

Researchers take first steps towards development of biosensor for detection of bacteria

Researchers from UPM have taken the first steps towards the development of a sensor for the detection of bacterial meningitis in real time by combining gravimetric sensors with synthetic antibodies giving, as a result, a sensitive, rapid and affordable method.

15 Sep 2017

Nexmos, Base Pair Biotechnologies create new class of DNA-aptamer based oxidation inhibitors

Base Pair Biotechnologies, Inc., The Aptamer Discovery Company, and Nexmos, Inc., the Aptamer Application R&D Company, announce the creation of a new class of DNA-aptamer based oxidation inhibitors.

30 Dec 2016

Protein-based CHD risk score developed

Researchers have screened over 1000 plasma proteins to develop a predictive score in patients with stable coronary heart disease.

22 Jun 2016

Scientists provide overview of most promising compounds to combat prostate cancer

Scientists from MIPT (Moscow Institute of Physics and Technology), MSU (Moscow State University), and National University of Science and Technology “MISIS” provided an overview of the most promising compounds which can be used as medications for prostate cancer.

23 Mar 2016

University of Oxford, SomaLogic partner to discover protein biomarkers for clinical diseases and conditions

The University of Oxford and SomaLogic announced today that they have agreed to undertake a number of collaborative projects that will employ SomaLogic's proprietary SOMAmer reagents and SOMAscan assay technologies to discover and characterize protein biomarkers for a range of clinical diseases and conditions.

8 Feb 2016